A carregar...
Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
The last 2 years have ushered in a new era in ovarian cancer therapy with the US Food and Drug Administration’s (FDA) approval of poly-ADP ribose polymerase (PARP) inhibitors (PARPi). One of the deadliest cancers that women experience, ovarian cancer, is most often diagnosed in advanced stages. Alth...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6223341/ https://ncbi.nlm.nih.gov/pubmed/30464492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S149248 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|